If you take, or are considering, a GLP-1 medication such as semaglutide or tirzepatide, you may have seen headlines over the past couple of years about a possible link between these drugs and suicidal thoughts. In January 2026, the FDA revisited that question and asked manufacturers to remove suicidal-thoughts warning language from several GLP-1 labels. Here is what that update says, what came before it, and what it does and does not change about how you and your clinician should think about mood during treatment.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation from a licensed clinician who knows your health history.
Why mood has been part of the conversation about GLP-1 medications
GLP-1 receptor agonists, including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound™), bring about significant changes in appetite, weight, and metabolic health for many people who use them. Any medication tied to that kind of change tends to draw attention to mood and mental health as part of routine safety monitoring, and GLP-1 medications were no exception.
Starting in 2023, regulators began reviewing postmarketing reports describing suicidal thoughts in some people taking GLP-1 receptor agonists for diabetes or weight management. A report on its own does not establish that a medication caused the event it describes, but a pattern of reports is the kind of signal drug safety systems are built to flag and investigate further. That investigation is what led to the FDA communications discussed below.
The FDA's January 2026 safety communication, and what changed
On January 13, 2026, the FDA issued a drug safety communication asking manufacturers to remove suicidal ideation and behavior warning language from the labels of three GLP-1 medications used for weight management: Saxenda® (liraglutide), Wegovy® (semaglutide), and Zepbound™ (tirzepatide). The agency said that a comprehensive review of the available data, including clinical trial results and postmarketing safety reports, did not find an increased risk of suicidal ideation or behavior associated with these medications.
Ozempic® (semaglutide approved for type 2 diabetes) was not named in the removal request, since its label did not carry this specific warning language in the first place. The update applies to the FDA-approved brand products named in the communication; it is a statement about those labels, not a new clinical trial result published on its own.
What the FDA's earlier 2024 review found, and why monitoring continued
This update revises an FDA communication from January 2024. That earlier review was prompted by postmarketing reports describing suicidal thoughts in people using GLP-1 receptor agonists. At the time, the FDA said its review had not identified a clear causal association between these medications and suicidal thoughts or actions, but added that it could not, at that point, definitively rule out a small risk. The agency said it would continue to monitor the data, including through a planned meta-analysis of clinical trials across GLP-1 products and a review of postmarketing data in the FDA's Sentinel surveillance system.
Throughout that period, the FDA's consistent message to patients was not to stop a prescribed GLP-1 medication on their own because of a mood-related concern, and instead to raise it with the prescribing clinician first. That guidance has not changed with the 2026 update.
Comparing the FDA's 2024 and 2026 positions
Because this topic has shifted over a couple of years, it can help to see the two FDA communications side by side rather than treating the news as a single, static fact:
| Timing | What the FDA said |
|---|---|
| January 2024 | Reviewing postmarketing reports; no clear causal link found, but a small risk could not be definitively ruled out; monitoring to continue |
| January 2026 | Comprehensive review complete; no increased risk of suicidal ideation or behavior found; removal of that warning language requested for Saxenda, Wegovy, and Zepbound |
What the updated guidance asks of clinicians
The FDA's current guidance asks health care professionals to discuss the updated findings directly with patients: that a comprehensive review did not find an increased risk of suicidal thoughts or behavior with these medications. At the same time, the agency asks clinicians to refer any patient who discloses suicidal thoughts or behavior to a mental health professional for evaluation, regardless of what the label says about population-level risk.
In practice, that means clinicians are still expected to ask about mood, depression history, and any prior suicidal thoughts as part of an individualized evaluation, the same way they would when considering any medication for a patient's health history. Clear communication between patient and clinician matters here in much the same way it matters for drug interactions, another area where your own clinician needs your full history to make a safe, individualized recommendation.
What patients are still asked to watch for and report
A label update is not the same as a green light to stop paying attention. Patients taking these medications are still asked to tell their health care professional about any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. If you are experiencing thoughts of suicide or self-harm, the FDA directs patients to call or text 988, the Suicide & Crisis Lifeline, which connects you with trained counselors any time of day.
None of this means GLP-1 medications are now considered a mental health risk that outweighs their intended use. It reflects a standard practice in medicine: mood and behavior are monitored as part of ongoing care for many chronic conditions, not just this medication class, and that monitoring does not disappear just because a specific warning was removed from a label.
Why weight management care often includes a mood conversation
Obesity and the conditions that often accompany it, including type 2 diabetes, sleep problems, and chronic pain, are themselves associated with a higher likelihood of depression and anxiety in the research literature. That overlap exists whether or not someone is taking a GLP-1 medication, which is one reason clinicians generally ask about mood as part of a broader evaluation, particularly in the first month of GLP-1 treatment, when the body is adjusting to a new medication and, often, meaningful changes in eating patterns.
Mood questions during treatment are not unique to GLP-1 medications. Clinicians ask similar questions when starting many long-term medications, precisely because new or worsening symptoms are easier to catch early when someone already knows to expect the question. If you are also tracking physical side effects of GLP-1 medications, mood is worth adding to that same ongoing conversation with your clinician, rather than treating it as a separate, less important topic.
When and how to reach out for support
If you notice new or worsening low mood, anxiety, irritability, or thoughts of suicide while taking a GLP-1 medication, the first step is to tell your prescribing clinician, even if you are not sure whether the medication is related. They can help sort out what is happening and decide, together with you, whether any change to your treatment plan is appropriate. Do not stop a prescribed medication on your own without talking to your clinician first, since stopping suddenly can have its own effects separate from any mood concern.
If you are in crisis or having thoughts of suicide right now, call or text 988 to reach the Suicide & Crisis Lifeline, or go to your nearest emergency room. These resources are available whether or not you take any medication, and reaching out is a reasonable, responsible step rather than an overreaction.
The bottom line
The FDA's January 2026 update reflects a comprehensive review that did not find an increased risk of suicidal thoughts or behavior with Saxenda, Wegovy, or Zepbound, and it revises an earlier, more cautious 2024 communication issued while that review was still underway. The update does not remove the general expectation that patients and clinicians keep talking about mood during treatment. If anything changes in how you feel, emotionally or otherwise, tell your clinician. You can find more articles like this one in our Weight Management section.
Important Safety Information
Indication. Semaglutide is FDA-approved as Ozempic® for type 2 diabetes and as Wegovy® for chronic weight management; tirzepatide is FDA-approved as Mounjaro® for type 2 diabetes and as Zepbound™ for chronic weight management; liraglutide is FDA-approved as Saxenda® for chronic weight management, each used alongside a reduced-calorie diet and increased physical activity. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These are often mild and tend to ease over time, particularly as the dose is increased gradually.
Warnings. These medications carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Tell your provider about any history of depression, suicidal thoughts, pancreatitis, gallbladder disease, kidney disease, or diabetic retinopathy, or if you are pregnant, planning to become pregnant, or breastfeeding. Report any new or worsening depression, unusual changes in mood or behavior, or thoughts of suicide to your prescribing clinician right away.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Did the FDA find that GLP-1 medications cause suicidal thoughts?
No. In its January 2026 safety communication, the FDA said a comprehensive review of clinical trial and postmarketing data did not find an increased risk of suicidal ideation or behavior associated with Saxenda, Wegovy, or Zepbound. This followed an earlier, more cautious 2024 review that had flagged postmarketing reports but could not definitively rule out a small risk at that time.
What changed with the FDA's January 2026 update?
The FDA asked manufacturers to remove suicidal ideation and behavior warning language from the labels of Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), based on a comprehensive review that found no increased risk. The update revises the FDA's January 2024 communication on the same topic.
Should I still tell my doctor about mood changes while taking a GLP-1 medication?
Yes. Even with the updated labeling, patients are still asked to report any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior to their prescribing clinician. Monitoring mood during treatment remains standard practice, independent of this specific label change.
What should I do if I'm having suicidal thoughts while on treatment?
Tell your prescribing clinician as soon as you can, and do not stop your medication on your own without talking to them first. If you are in crisis, call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.
Does this FDA update apply to compounded semaglutide or tirzepatide?
The FDA's January 2026 communication named the FDA-approved brand products Saxenda, Wegovy, and Zepbound. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality, so this label change does not apply to them directly; people using a compounded version should rely on guidance from their own prescribing clinician.
Can GLP-1 medications affect mood in other ways, like irritability or anxiety?
Clinicians generally ask about mood, sleep, and overall well-being throughout GLP-1 treatment as part of routine monitoring, the same way they would for many long-term medications. If you notice any change in mood, including irritability or anxiety, it is worth mentioning to your clinician so it can be evaluated alongside the rest of your health history.
